[EDRF].
Okamura
Tomio
T
Department of Pharmacology, Shiga University of Medical Science.
D053607:Adrenomedullin; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D017630:Connexins / Q000502:physiology; D052246:Cyclooxygenase 2 Inhibitors; D045462:Endothelium-Dependent Relaxing Factors / Q000502:physiology; D011464:Epoprostenol / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D020098:Natriuretic Peptide, C-Type / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D052250:Nitric Oxide Synthase Type III / Q000502:physiology; D010455:Peptides / Q000502:physiology
D017630:Connexins; D052246:Cyclooxygenase 2 Inhibitors; D045462:Endothelium-Dependent Relaxing Factors; D010455:Peptides; D020098:Natriuretic Peptide, C-Type; D053607:Adrenomedullin; D009569:Nitric Oxide; D011464:Epoprostenol; D052250:Nitric Oxide Synthase Type III